Henry Cohen
Kingsbrook Jewish Medical Center
44 Papers
115 Citations
Henry Cohen is an academic researcher from Kingsbrook Jewish Medical Center. The author has contributed to research in topics: Medicine & Intensive care unit. The author has an hindex of 13, co-authored 44 publications. Previous affiliations of Henry Cohen include Touro College & Long Island University.
Chat about Author
Papers
Improving long-term outcomes after discharge from intensive care unit: report from a stakeholders' conference.
Dale M. Needham,Judy E. Davidson,Henry Cohen,Ramona O. Hopkins,Craig R. Weinert,Hannah Wunsch,Christine Zawistowski,Anita Bemis-Dougherty,Susan C Berney,O. Joseph Bienvenu,Susan Brady,Martin B. Brodsky,Linda Denehy,Doug Elliott,Carl Flatley,Andrea L. Harabin,Christina Jones,Deborah Louis,Wendy Meltzer,Sean R. Muldoon,Jeffrey B. Palmer,Christiane Perme,Marla Robinson,David M. Schmidt,Elizabeth Scruth,Gayle R. Spill,C. Porter Storey,Marta L. Render,John Votto,Maurene A. Harvey +29 more
TL;DR: Improving care for intensive care survivors and their families requires collaboration between practitioners and researchers in both the inpatient and outpatient settings, and three major themes emerged from the conference.
2.3K
Off-label medication use in adult critical care patients
Ishaq Lat,Scott T. Micek,Jeffrey Janzen,Henry Cohen,Henry Cohen,Keith M. Olsen,Curtis E. Haas +6 more
TL;DR: The use of off-label medication therapies in the US adult critical care units is common, a majority of which are initiated after admission to the ICU and a significant portion ofWhich are supported with inferior levels of evidence.
57
Optimal Low-Density Lipoprotein Cholesterol Lowering—Morning Versus Evening Statin Administration:
Roda Plakogiannis,Henry Cohen +1 more
TL;DR: There are sufficient data to support evening administration of simvastatin to achieve optimal lowering of LDL-C levels, according to a review of clinical evidence evaluating the chronobiologic effects of morning versus evening statin administration.
50
Bosentan therapy for pulmonary arterial hypertension
TL;DR: Prostacyclin analogues are the most effective agents for managing PAH, but their use is hampered by the need for parenteral therapy and oral bosentan is a novel treatment alternative for patients with PAH.
34
Using technology to prevent adverse drug events in the intensive care unit.
TL;DR: This classification provides a way of determining how ADE-preventing technologies in the intensive care unit can be successfully integrated into clinical practice by identifying the factors essential for success.
28